Enzymatica AB (FRA:EN9) Research & Development: €1.22 Mil (TTM As of Mar. 2026)


FRA:EN9 Enzymatica AB FRA:EN9
36 GF Score
Price €0.20
GF Value €0.17
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB Research & Development?

Enzymatica AB FRA:EN9 +3.17% 36 Research & Development is €1.22 Mil as of Mar. 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 36/100 and a GF Value™ of €0.17 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Enzymatica AB's Research & Development for the three months ended in Mar. 2026 was €0.26 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €1.22 Mil.

Enzymatica AB  (FRA:EN9) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Enzymatica AB Research & Development Related Terms

Enzymatica AB Research & Development Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Research & Development Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.36 2.41 1.37 1.34 1.44

Enzymatica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.36 0.24 0.36 0.26
FRA:EN9
36GF Score
Enzymatica AB FRA:EN9
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €1.22 Mil mean?
Enzymatica AB (FRA:EN9) has a Research & Development of €1.22 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Enzymatica AB and its competitors.
Is Enzymatica AB's Research & Development too high?
Enzymatica AB's current Research & Development is €1.22 Mil. Overall, Enzymatica AB has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Research & Development compare to ZTS and UTHR?
Enzymatica AB's Research & Development of €1.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current Research & Development is €1.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.20 — trading 14.7% above its estimated fair value. The current Research & Development is €1.22 Mil. Enzymatica AB's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Research & Development is €1.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.20 is trading 14.7% above its estimated GF Value™ of €0.17. GuruFocus considers Enzymatica AB to be Modestly Overvalued.

Key valuation signals for FRA:EN9:

  • Research & Development: €1.22 Mil
  • GF Value™: €0.17 vs. price of €0.20 (14.7% above fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
36GF Score

Get the complete analysis for FRA:EN9

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.17
GF Value